CHAPEL HILL, N.C., Sept. 28 /PRNewswire/ -- The landscape of scientific publications strategy, planning and delivery is changing with the advent of transparency guidelines. Half of global publications groups are fully located in the marketing function, but publications leaders expect to see a shift to medical groups to diminish the marketing influence, according to primary research conducted by Best Practices, LLC's Business Excellence Board (BEB).
In fact, 14 percent of pharmaceutical and biotech companies in the study do not turn to global or regional marketing representatives to develop a global publications strategy and plan. These companies, which align publications strictly with the medical group, receive strategy input from medical directors, advisor physicians and biostatisticians.
Download a complimentary white paper of this client-driven research, "Scientific Publications Strategy: Managing Reputation, Clinical Trial Results and Commercial Relevance," at http://www3.best-in-class.com/br103.htm. The study guides pharmaceutical and biotechnology companies in making the transition to the new publishing environment while building scientific credibility and commercial success.
Other key topic areas in the research include:
-- Impact of transparency guidelines on publications, planning and
-- Tactics for handling publication of neutral or negative clinical trial
-- Optimal structure for the global publications function;
-- Transition of global publication function from commercial to clinical;
-- Strategy changes for the new marketplace.
This research sample represents one tool available to members in the
BEB. Members can request benchmarking surveys and best practice research,
assessment of current processes, targeted executive interviews, comparison
case studies and recommendations fo
|SOURCE Best Practices, LLC|
Copyright©2007 PR Newswire.
All rights reserved